acne vulgaris
Women's health · 2009–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals National Aboriginal Community Controlled Health Organisation |
| drospirenone with ethinylestradiol Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using… | Nov 2024 | Recommended | 1 individuals National Aboriginal Community Controlled Health Organisation |
| clindamycin phosphate with benzoyl peroxide Treatment of moderate acne vulgaris with inflammatory lesions in patients with an inadequate response to a minimum of two over-the-counter products. | Mar 2009 | Not recommended | no section in document |
Who spoke
National Aboriginal Community Controlled Health Organisation
What the PBS pays
$12M in government benefit over 2024–25, across 653,426 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| drospirenone with ethinylestradiol | $7.2M |
| clindamycin phosphate with benzoyl peroxide, gel | $5.1M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| clascoteroneClascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) | TA1105 | terminated | 2025-10 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| trifaroteneAKLIEF trifarotene 50 microgram/g cream bottle | 2021 | 2 |
| clascoteroneWINLEVI clascoterone 1% w/w cream tube | 2024 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.